Related Experiment Video
Updated: Sep 1, 2026
Autologous Endothelial Progenitor Cell-Seeding Technology and Biocompatibility Testing For Cardiovascular Devices in Large Animal Model
Published on: September 9, 2011
Two years experience with Medtronic-Hall prostheses in 75 patients with special reference to its thrombogenicity and
Insights
The Medtronic-Hall valve showed favorable outcomes in 75 patients over 24 months, with low mortality and no thromboembolic events. Mild hemolysis was observed, but was lower in specific prosthesis types.
Area of Science:
- Cardiology
- Cardiac Surgery
- Biomaterials Science
Background:
- The Medtronic-Hall valve is a mechanical prosthesis used in cardiac surgery.
- Evaluating the long-term performance and complications of prosthetic heart valves is crucial for patient management.
Purpose of the Study:
- To assess the safety and efficacy of the Medtronic-Hall valve prosthesis.
- To compare the Medtronic-Hall valve outcomes with other mechanical prostheses.
Main Methods:
- A retrospective analysis of 75 patients who received 80 Medtronic-Hall valve prostheses over 24 months.
- Data collection included patient demographics, surgical indications, operative outcomes, complications, and follow-up events.
- Assessment of hemolysis, hemorrhagic complications, prosthetic valve endocarditis (PVE), and thromboembolic episodes.
Main Results:
- Overall mortality was 8% (6 deaths), with 4 early and 2 late deaths.
- Four patients required re-operation for paravalvular leaks; 3 survived.
- Mild subclinical hemolysis was common but significantly lower in type D 16 prostheses; no thromboembolic episodes occurred.
Conclusions:
- The Medtronic-Hall valve demonstrated favorable short-term outcomes with acceptable morbidity and mortality.
- The prosthesis showed a low incidence of severe complications, including thromboembolism and endocarditis.
- Further studies may be warranted to explore the long-term durability and specific advantages of the Medtronic-Hall valve in different patient populations.
Abstract:
Seventy-five patients received 80 Medtronic-Hall valve prostheses during a 24-month period at the Beilinson Medical Center. The mean age was 50 years and the majority of patients had rheumatic heart disease. All operations were elective. There were 4 early and 2 late deaths (8%). Four patients needed re-operation for paravalvular leaks, 3 of them survived the second operation and one patient with prosthetic valve endocarditis did not. One patient was re-operated on successfully because of a mycotic aneurysm in the ascending aorta. Mild subclinical hemolysis (elevated SLDH and reduced haptoglobin) was found in the majority of patients. Hemolysis was found to be significantly lower in type D 16 prostheses patients. Mild hemorrhagic complications occurred in 2 patients due to anticoagulant therapy. Three patients suffered from prosthetic valve endocarditis (PVE), 2 of them responded to prompt medical therapy. There were no thromboembolic episodes. Most surviving patients experienced marked postoperative improvement. Within the 24-month follow-up period, the Medtronic-Hall valve compared favorably with other disk or ball prostheses previously and currently used in our department.
